Press Releases

The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Canget BioTekpharma LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.

In recognition of his dedication toward advancements in lung cancer care as well as his contributions as a valued mentor, Roswell Park Comprehensive Cancer Center Chair of Thoracic Surgery, Sai Yendamuri, MD, MBA, FACS, has recently been honored with prestigious leadership roles, awards, and grant funding from both local and national organizations.

Following a national search, Roswell Park Comprehensive Cancer Center has selected George T. “Buddy” Hickman as its new Chief Digital & Information Officer. Hickman succeeds Tom Furlani, PhD, who retires this month.

Roswell Park Comprehensive Cancer Center has launched registration for the fourth annual IceCycle fundraising event, presented by the West Herr Automotive Group. This event is bringing together 13 WNY fitness studios and more than 1,000 participants on March 8 and 9 to take a 45-minute cycling class on ice while raising funds for research and programs at Roswell Park. 

Ahead of the new year, Roswell Park Comprehensive Cancer Center celebrates the 136 physicians across 34 specialties named to Buffalo Spree magazine’s Top Doctors list for 2024. The annual list is compiled through surveys submitted by Western New York physicians.

In recognition of the countless hours she has dedicated to designing and leading practice-changing research and advocating for higher standards of care for children and young adults with cancer, Roswell Park Comprehensive Cancer Center Chair of Pediatrics Kara Kelly, MD, has been honored with both awards and new leadership positions by several national and international oncology organizations.

Senator Tim Kennedy joined pediatric hematologist/oncologist Steven Ambrusko MD, MS, at Roswell Park Comprehensive Cancer Center to urge the New York State Department of Health to expedite the coverage approval process for a new groundbreaking gene therapy that is being hailed as a cure for sickle cell disease.

St. Joseph’s Health and Roswell Park are proud to announce the launch of a groundbreaking Cancer Care service line, bringing exceptional oncology services to Central New York.

A single infusion of the CAR T cell therapy ciltacabtagene autoleucel produced deep, durable responses in multiple myeloma patients whose disease had progressed after initial therapy. Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park, shared the updated results in an oral abstract session at he American Society of Hematology (ASH) annual meeting.